Patent Rights vs Public Health: India's Structural Struggle
India’s patent policy is failing its constitutional commitment to public health. The legal architecture, designed to balance intellectual property rights with societal health needs, remains inadequately operationalized. Despite robust safeguards under the Patents Act, 1970 and flexibilities provided by the TRIPS Agreement, India’s cautious approach to leveraging these tools weakens its position as the ‘pharmacy of the Global South’. The underlying issue lies in structural compromises: appeasing international trade pressures often overrides domestic health imperatives. Unless decisive policy reforms address this imbalance, India risks institutionalizing inequity.
The Institutional Landscape: Patents Act, TRIPS, and Article 21
India’s patent regime operates under the dual framework of domestic law and international obligations. Domestically, the Patents Act, 1970, amended in 2005, contains critical provisions to protect public health—Section 3(d) prevents 'evergreening'; Sections 84 and 92 authorize compulsory licensing; Section 47(4) permits state use of patented inventions; and Section 66 allows revocation of patents prejudicial to public interest. Internationally, India adheres to the WTO’s TRIPS Agreement, which protects patent rights but permits flexibilities like compulsory licensing under the Doha Declaration, 2001. However, these mechanisms depend on government decisiveness in invoking them.
Moreover, India’s constitutional commitment under Article 21—interpreted by the Supreme Court to include the right to health—provides a legal obligation to ensure equitable access to medicines. Policy implementation, however, often sacrifices this right at the altar of trade diplomacy and investor confidence. One glaring example is India’s hesitant application of compulsory licenses, with only one granted since 2012 (Natco Pharma vs Bayer Corp, 2012), despite affordable medicine shortages.
Data Points: Evidence of Systemic Failures
- India spends less than 1% of GDP on R&D, compared to 2.5–3% in developed nations, crippling domestic pharmaceutical innovation.
- Patented medicines cost 10–30 times more than generics, pushing millions into catastrophic health expenditures.
- The US pressures India via its Trade Representative’s Priority Watch List, heightening scrutiny of patent policies perceived as unfair.
- Competition authorities remain inactive against abusive practices like 'patent clustering', violating The Competition Act, 2002.
Despite claims to safeguard public health, India’s institutional inertia erodes the efficacy of its legal frameworks. The government has failed to initiate large-scale rural pharmaceutical distribution systems for patented medicines. Dependency on private healthcare—where drug prices remain unregulated—exacerbates inequities.
Challenging Evergreening: Legal Safeguards and Gaps
Evergreening—where patentees modify existing drugs to extend monopoly protection—is rampant. Section 3(d) of the Patents Act theoretically blocks frivolous patents but lacks clear enforcement protocols. The landmark Novartis vs Union of India (2013) case exposed attempts to circumvent this provision, rejecting Novartis's patent application for an altered cancer drug (Glivec). Nevertheless, multinational pharmaceutical firms continue exploiting technical loopholes, delaying generic entry and inflating drug prices.
Price control via the National Pharmaceutical Pricing Authority (NPPA) is another key instrument, yet remains restricted to certain drug categories. This fails to alleviate the financial burden for life-saving patented drugs, especially in cases like cancer therapies and HIV treatments. A proactive policy mix, integrating broader price-control mechanisms with TRIPS flexibilities, could ameliorate access costs.
The Global North’s Pressure: Trade Retaliation as a Constraint
The strongest counter-argument to India’s aggressive use of TRIPS flexibilities comes from the Global North. The United States and EU consistently argue that policies like compulsory licensing discourages innovation. In retaliation, the US leverages its “Priority Watch List” and threatens sanctions or trade restrictions. Proponents claim that curbing monopoly protections could deter foreign investment and stifle pharmaceutical R&D within India.
While these claims deserve engagement, available evidence demonstrates otherwise. Affordable medicines catalyze public health outcomes, increasing productivity and reducing state healthcare burdens. Moreover, countries like South Africa have successfully invoked compulsory licenses without jeopardizing foreign trade relations. India’s cautious approach reflects political hesitations more than economic necessity.
International Perspective: South Africa’s Assertive Patent Regime
India could draw lessons from South Africa’s patent reform strategy, which vigorously prioritizes public health. Under the 2017 Intellectual Property Policy, South Africa allows broad compulsory licensing applications, strengthening access to medicines for HIV/AIDS patients. Unlike India, South Africa also resists foreign pressure—rejecting overt trade threats from lobbying nations. In comparison, India’s sporadic invocation of TRIPS flexibilities reveals an inconsistent commitment to public health. What India calls dual obligations under TRIPS, South Africa asserts as sovereign rights.
Assessment: Balancing Sovereignty, Innovation, and Health
India’s patent policy, though legally robust, suffers from weak enforcement, diplomatic capitulations, and a fragmented healthcare infrastructure. The structural solutions lie in empowering domestic legislation over external pressures. A National Patent Policy aligned with health priorities, coupled with aggressive use of TRIPS flexibilities and indigenous R&D promotion, remains imperative. The Competition Commission, NPPA, and Patent Office must coordinate efforts to ensure equitable access without deterring innovation.
Ultimately, India needs to embrace its identity as the "pharmacy of the Global South," turning legal potential into actionable policy. Legislative amendments and political will are prerequisites to mitigating the tension between patent protection and public health guarantees under Article 21.
Practice Questions for UPSC
Prelims Practice Questions
- 1. The Patents Act, 1970 includes provisions for compulsory licensing.
- 2. India has issued multiple compulsory licenses since 2012.
- 3. Patent evergreening is effectively prevented by current enforcement mechanisms.
Which of the above statements is/are correct?
- 1. Increased accessibility to affordable medicines.
- 2. Heightened scrutiny from the US Trade Representative.
- 3. Enhanced domestic pharmaceutical innovation.
Which of the above statements is/are correct?
Frequently Asked Questions
What are the main shortcomings of India's patent policy in relation to public health?
India's patent policy is currently failing to align with its constitutional obligation to ensure public health. The legal frameworks in place, such as the Patents Act, 1970, and flexibilities under the TRIPS Agreement, have not been effectively operationalized, leading to compromises that favor international trade over domestic health needs.
How do international obligations affect India's patent regime?
India's patent regime is influenced by both domestic laws and international obligations, particularly the TRIPS Agreement. Although this agreement allows for certain flexibilities, such as compulsory licensing, India's cautious invocation of these provisions limits its ability to address urgent public health issues effectively.
What does Article 21 of the Indian Constitution encompass in the context of public health?
Article 21 of the Indian Constitution has been interpreted to include the right to health, establishing a legal obligation for the state to provide equitable access to healthcare. However, implementation often conflicts with trade diplomacy, compromising public health access for the sake of investor confidence.
What measures exist under the Patents Act, 1970 to protect public health?
The Patents Act, 1970 includes several provisions aimed at protecting public health, such as Section 3(d), which prevents 'evergreening', and Sections 84 and 92, which authorize compulsory licensing. However, the effectiveness of these provisions depends on the government's willingness to implement them decisively.
How does the example of South Africa inform India’s patent policies?
South Africa's approach to patent reform highlights the potential for a more assertive stance in prioritizing public health without alienating trade relations. By leveraging compulsory licensing more aggressively than India, South Africa demonstrates that it is possible to improve access to medicines while maintaining productive international relations.
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.